Patents Assigned to Transgenex Nanobiotech, Inc.
-
Patent number: 11319311Abstract: Synthesis and characterization of novel DACT forms suitable for pharmaceutical compositions in drug delivery systems to treat cancer in humans or a warm-blooded mammals. The novel forms include but not limited to cocrystals, salts, solvates of salts, and mixtures thereof.Type: GrantFiled: February 11, 2019Date of Patent: May 3, 2022Assignee: TRANSGENEX NANOBIOTECH, INC.Inventors: Mazen Hanna, Manomi Perera, Jiyu Yan, Andrew Hanna
-
Patent number: 11053254Abstract: Synthesis and characterization of novel crystalline mitomycin C forms suitable for pharmaceutical compositions in drug delivery systems to treat human or warm-blooded diseases.Type: GrantFiled: February 11, 2019Date of Patent: July 6, 2021Assignee: TRANSGENEX NANOBIOTECH INC.Inventors: Mazen Hanna, Manomi Perera, Jiyu Yan, Andrew Hanna
-
Patent number: 11016062Abstract: A novel SH-SAW biosensor capable of non-invasive and touch-free detection of cancer cell viability and growth or proliferation in two-dimensional (2D) and three-dimensional (3D) cell cultures as well as stem cell regeneration as it pertains to cancer cell biology and anti-cancer drug development is presented. The biosensor includes two pairs of resonators including interdigital transducers reflecting fingers to quantify mass loading by the cells in suspension as well as within a tumoroid culture platform. The biosensor can be part of a perfused 3PNS-tumoroid system that is amenable to real-time non-invasive monitoring of the cell proliferation, viability, and multiplexed detection of key physiologic and clinical biomarkers.Type: GrantFiled: December 20, 2019Date of Patent: May 25, 2021Assignees: University of South Florida, TransGenex Nanobiotech, Inc.Inventors: Shyam S. Mohapatra, Subhra Mohapatra, Rasim Oytun Guldiken, Rajesh R. Nair, Tao Wang
-
Patent number: 10813935Abstract: Disclosed herein are compositions and methods for treating cancer. Further provided herein are compositions and methods for reducing, inhibiting, or preventing resistance of cancer to tyrosine kinase inhibitors. The methods may include administering an anti-resistance agent such as a CYP51A1 inhibitor or an agonist of miRNA-764 (SEQ ID NO: 4) to a subject. A tyrosine kinase inhibitor may also be administered to the subject in addition to the anti-resistance agent.Type: GrantFiled: February 23, 2018Date of Patent: October 27, 2020Assignees: TRANSGENEX NANOBIOTECH, INC., University of South FloridaInventors: Subhra Mohapatra, Shyam S. Mohapatra, Mark Howell, Rajesh Nair
-
Publication number: 20200141905Abstract: A novel SH-SAW biosensor capable of non-invasive and touch-free detection of cancer cell viability and growth or proliferation in two-dimensional (2D) and three-dimensional (3D) cell cultures as well as stem cell regeneration as it pertains to cancer cell biology and anti-cancer drug development is presented. The biosensor includes two pairs of resonators including interdigital transducers reflecting fingers to quantify mass loading by the cells in suspension as well as within a tumoroid culture platform. The biosensor can be part of a perfused 3PNS-tumoroid system that is amenable to real-time non-invasive monitoring of the cell proliferation, viability, and multiplexed detection of key physiologic and clinical biomarkers.Type: ApplicationFiled: December 20, 2019Publication date: May 7, 2020Applicants: University of South Florida, TransGenex Nanobiotech, Inc.Inventors: Shyam S. Mohapatra, Subhra Mohapatra, Rasim Oytun Guldiken, Rajesh R. Nair, Tao Wang
-
Patent number: 10520472Abstract: A novel SH-SAW biosensor capable of non-invasive and touch-free detection of cancer cell viability and growth or proliferation in two-dimensional (2D) and three-dimensional (3D) cell cultures as well as stem cell regeneration as it pertains to cancer cell biology and anti-cancer drug development is presented. The biosensor includes two pairs of resonators including interdigital transducers reflecting fingers to quantify mass loading by the cells in suspension as well as within a tumoroid culture platform. The biosensor can be part of a perfused 3PNS-tumoroid system that is amenable to real-time non-invasive monitoring of the cell proliferation, viability, and multiplexed detection of key physiologic and clinical biomarkers.Type: GrantFiled: August 21, 2017Date of Patent: December 31, 2019Assignees: University of South Florida, TransGenex Nanobiotech, Inc.Inventors: Shyam S. Mohapatra, Subhra Mohapatra, Rasim Oytun Guldiken, Rajesh R. Nair, Tao Wang
-
Publication number: 20180045681Abstract: A novel SH-SAW biosensor capable of non-invasive and touch-free detection of cancer cell viability and growth or proliferation in two-dimensional (2D) and three-dimensional (3D) cell cultures as well as stem cell regeneration as it pertains to cancer cell biology and anti-cancer drug development is presented. The biosensor includes two pairs of resonators including interdigital transducers reflecting fingers to quantify mass loading by the cells in suspension as well as within a tumoroid culture platform. The biosensor can be part of a perfused 3PNS-tumoroid system that is amenable to real-time non-invasive monitoring of the cell proliferation, viability, and multiplexed detection of key physiologic and clinical biomarkers.Type: ApplicationFiled: August 21, 2017Publication date: February 15, 2018Applicants: University of South Florida, TransGenex Nanobiotech, Inc.Inventors: Shyam S. Mohapatra, Subhra Mohapatra, Rasim Oytun Guldiken, Rajesh R. Nair
-
Publication number: 20100105024Abstract: A rapid test kit may have a genetic probe, and antibody detecting probe or a combination of a genetic probe and an antibody detecting probe disposed within one or more test windows of the test kit. A cellulose filter paper membrane with a flow rate selected in a range of about 0.04 to about 0.4 ml/min/cm2 is used in one example. The test kit provides for rapid screening for DNA, RNA or fragments of DNA or RNA in a bodily fluid or antibodies indicating exposure to such DNA/RNA. The genetic probe may include single stranded DNA or a fragment of single stranded DNA, such as primer, immobilized on the filter paper, and a single stranded DNA, such as the same or a different primer, conjugated with a marker, such as a nanotube or nanoparticle. For example, a gold nanoparticle or a carbon nanotube may be used as a staining agent by conjugating the gold nanoparticle or the carbon nanotube to a genetic probe, such as a DNA primer capable of binding with a complementary DNA or viral RNA or a fragment of one of these.Type: ApplicationFiled: April 16, 2009Publication date: April 29, 2010Applicant: Transgenex Nanobiotech, Inc.Inventors: Weidong Xu, Shyam Mohapatra, Arun Kumar